AI-generated analysis. Always verify with the original filing.
Neurogene Inc. announced full year 2025 financial results, reporting net loss of $90.4 million, R&D expenses of $75.0 million, G&A expenses of $28.3 million, and cash, cash equivalents and short-term investments of $269.0 million as of December 31, 2025, providing runway through first quarter of 2028. Highlights include 100% enrollment in Embolden registrational trial for NGN-401, >50% participants dosed, and FDA Breakthrough Therapy designation.
Event Type
Disclosure
Mandatory
Variant
8-K
and Exhibit s 99.1 and 99.2 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated March 24, 2026 99.2 Corporate Presentation (March 2026) 104
| Metric | Value | Basis |
|---|---|---|
| Net Loss | $90.40 | GAAP |
| Research & Development (R&D) Expenses | $75.00 | GAAP |
| General & Administrative (G&A) Expenses | $28.30 | GAAP |